Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRIS)

Curis Provides Third Quarter 2024 Business Update

PR Newswire 12 days ago

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

PR Newswire November 7, 2024

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

PR Newswire October 29, 2024

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

PR Newswire September 23, 2024

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 17, 2024

Curis to Present at Upcoming Healthcare Conferences in September

PR Newswire September 4, 2024

Curis Provides Second Quarter 2024 Financial and Operating Update

PR Newswire August 1, 2024

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

PR Newswire July 25, 2024

Curis to Present at Upcoming Healthcare Conference in July

PR Newswire July 10, 2024
View More News ››

Opinion & Analysis (NDAQ:CRIS)

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Streetwise Reports June 11, 2020
View More Opinion ››

Bullboard Posts (NDAQ:CRIS)

Curis (NASDAQ:CRIS) Reports Promising Progress in Advancing

http://beyondspx.com/2024/08/02/curis-nasdaqcris-reports-promising-progress-in-advancing-emavusertib-across-key-hematological...
MikeTester - August 3, 2024

Buy Recommendation Issued On CRIS By Piper Sandler

JUST IN: $CRIS Buy Recommendation Issued On CRIS By Piper Sandler2024-02-09 10:15:03 ET Piper Sandler analyst issues BUY recommendation...
whytestocks - February 9, 2024

should be a good year here

for this stock,so glta.
coolfooldumbguy - March 31, 2019

it's a buy today for me

it looks like it will perform this year,so glta.
coolfooldumbguy - March 25, 2019

STELLAR RESULTS!

Curis Reports First Quarter 2016 Financial Results CRIS | 49 minutes ago  ...
Interpolation1 - May 9, 2016

CURIS PRESENTING IN JUST OVER A WEEK!

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual...
Interpolation1 - April 11, 2016
View more Bullboard ››

Nanalysis Scientific Corp.

Nanalysis Scientific Corp.

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for ...
View More »